Figure 5From: Radiochemoimmunotherapy with intensity-modulated concomitant boost: interim analysis of the REACH trialOverall progression-free survival (PFS) (n = 14 pts). PFS at 1 year: 84.4%; PFS at 2 years 63.3%.Back to article page